LIGAND PHARMACEUTICALS INC
LGNXZDrugs in Pipeline
7
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Targretin Gel 1%
Alopecia Areata
Bexarotene
Lung Cancer
lasofoxifene
Osteoporosis
Budesonide + Azelastine
Seasonal Allergic Rhinitis
Budesonide
Seasonal Allergic Rhinitis
erlotinib and bexarotene
Carcinoma, Non-small-cell Lung
Alitretinoin
Sarcoma, Kaposi
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Targretin Gel 1% | Phase 3 | Alopecia Areata | - | - |
Bexarotene | Phase 2 | Lung Cancer | - | - |
lasofoxifene | Phase 2 | Osteoporosis | - | - |
Budesonide + Azelastine | Phase 2 | Seasonal Allergic Rhinitis | - | - |
Budesonide | Phase 2 | Seasonal Allergic Rhinitis | - | - |
erlotinib and bexarotene | Phase 2 | Carcinoma, Non-small-cell Lung | - | - |
Alitretinoin | Phase 2 | Sarcoma, Kaposi | - | - |
Frequently asked questions
What is in LIGAND PHARMACEUTICALS INC's drug pipeline?→
CatalystAlert tracks 7 drug candidates in LIGAND PHARMACEUTICALS INC's (LGNXZ) pipeline across Phase 3, Phase 2. Its lead program is Targretin Gel 1% (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is LIGAND PHARMACEUTICALS INC's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for LIGAND PHARMACEUTICALS INC (LGNXZ) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track LGNXZ biotech catalysts?→
Add LGNXZ to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow LIGAND PHARMACEUTICALS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.